Bevacizumab, a humanized anti-VEGF-A monoclonal antibody, was approved by the FDA for the treatment of NSCLC in 2006 [27] and for the treatment of recurrent glioblastoma in 2009 [75]. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.